Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO.

Created on 08 Nov 2026

Authors

Gareth P Gregory, Jeremy S Abramson, Huiqiang Huang, Qingyuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Estefania Mulvihill, Martine Kallemeijn, Murali Kesavan, Richard Ta, Voleak Choeurng, Linda Lundberg, Huilai Zhang

Published in

Clinical lymphoma, myeloma & leukemia. Oct 11, 2026. Epub Oct 11, 2026.

Abstract

The phase III STARGLO study (NCT04408638) demonstrated an overall survival benefit with glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus gemcitabine and oxaliplatin (R-GemOx) in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Here, the impact of treatment on patient-reported outcomes (PROs) in STARGLO was evaluated.
Patients were randomized 2:1 to Glofit-GemOx or R-GemOx. PROs were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Functional Assessment of Cancer Treatment-Lymphoma Lymphoma Subscale throughout treatment and follow-up. Endpoints included time to deterioration (TTD) and change from baseline in functioning and symptoms.
Overall, 274 patients were enrolled (Glofit-GemOx, n = 183; R-GemOx, n = 91). PRO questionnaire response rates were 100% at baseline and > 90% on treatment. Baseline scores indicated moderate-to-high functioning and low-to-moderate symptom severity. Glofit-GemOx had nominal delays in median TTD versus R-GemOx for physical functioning (9.1 vs 8.2 months), fatigue (1.7 vs 1.4 months), and lymphoma symptoms (6.2 vs 4.5 months). Glofit-GemOx-treated patients achieved clinically meaningful improvements in pain and lymphoma symptoms earlier (by Cycle 3) than R-GemOx-treated patients. At end of treatment, pain improvements were maintained in Glofit-GemOx-treated patients, whereas scores for R-GemOx-treated patients returned to pre-treatment baseline.
Glofit-GemOx maintained health-related quality of life and physical functioning, while providing earlier relief of pain and lymphoma symptoms versus R-GemOx. These findings align with the clinical benefits observed with Glofit-GemOx versus R-GemOx in STARGLO, further supporting Glofit-GemOx as a treatment option for relapsed/refractory DLBCL.

PMID:
42998919
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement